Gauging the Long-Term Benefits of Ipilimumab in Melanoma

J Clin Oncol. 2015 Jun 10;33(17):1865-6. doi: 10.1200/JCO.2014.59.5041. Epub 2015 Feb 9.

Authors

Antoni Ribas¹, Keith T Flaherty²

Affiliations

¹ University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, CA aribas@mednet.ucla.edu.
² Massachusetts General Hospital Cancer Center, Boston, MA.

PMID: 25667273
DOI: 10.1200/JCO.2014.59.5041

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Humans
Melanoma / drug therapy*
Skin Neoplasms / pathology*

Substances

Antibodies, Monoclonal
Antineoplastic Agents